AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome.

Eur Heart J · 2026 · PMC12777704 · PMID 40884219

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Additionally, KCNQ1 -SupRep reduced QT dispersion and showed a trend towards a reduced EAD incidence, further supporting its protective effects.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.